|Mr. Michael W. Nall||CEO, Pres & Director||598.56k||N/A||1963|
|Mr. Timothy C. Kennedy||CFO, COO & Corp. Sec.||460.59k||N/A||1958|
|Dr. Soon Kap Hahn Ph.D.||Founder||N/A||N/A||N/A|
|Mr. Pavel Tsinberg||Director of Technology Devel.||N/A||N/A||N/A|
|Mr. Michael W. Brown||Gen. Counsel and Compliance & Privacy Officer||N/A||N/A||N/A|
|Mr. David S. Moskowitz R.Ph., MBA||VP of Strategy & Corp. Communications||N/A||N/A||N/A|
|Mr. Michael Terry||Sr. VP of Corp. Devel.||N/A||N/A||1955|
|Ms. Brenda Tang||Sr. Director of Marketing||N/A||N/A||N/A|
|Mr. Gary Marchetti||Sr. Director of People & Culture/Facilities||N/A||N/A||N/A|
|Dr. Veena M. Singh||Sr. Medical Director||N/A||N/A||1975|
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. Its Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from circulating tumor DNA; and Target-Selector CTC and molecular platforms provide biomarker detection and monitoring capabilities. In addition, it offers laboratory services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians. Further, it is developing PCR-based assays for detecting the COVID-19 virus. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Biocept, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.